Overview of Postmarketing Drug Safety Reporting Requirements - REdI 2020

(35:16)

Postmarketing Drug Safety Compliance: 2019 Inspection Findings

(59:1econd)

Protecting Patients from Bad Drugs: A Risk-Based approach to medicines quality surveillance (Part 1)

(20:23)

FDA's Sentinel Initiative - Pharmacovigilance 2020

(54:27)

Postmarketing Adverse Drug Experience (PADE) Inspections – (1of3) Jun. 19, 2018

(1:3:54)

Post Marketing Surveillance | Clinical Development of Drug | Clinical Research |

(4:11)

Pharmacovigilance: Ensuring the safety of drugs

(1:3:39)

Postmarket Safety Surveillance: Tools, Methods, and Benefit-Risk Framework - Pharmacovigilance 2020

(56:41)

The Importance of Generic Drug Pharmacovigilance (9of16) Generic Drugs Forum 2020

(1:6:1econd)

Requirements from regulatory agencies and post marketing surveillance - G.M.C. Rosano

(30:7)

Preventing Medication Errors: Lessons Learned from Postmarket Safety Surveillance– Pharmacovigilance

(29:21)

Postmarketing Safety Management

(1:55)

Electronic Submission of Adverse Event Reports to FAERS using ICH E2B(R3) Standards - Oct. 11, 2019

(59:21)

Nonprescription Drug Product with an Additional Condition for Nonprescription Use

(55:40)

Challenges in Generic Drug Safety and Surveillance (6of27) Generic Drugs Forum 2018

(18:47)

Post-Marketing Surveillance of Full-Spectrum Hemp Extract CBD Products for Reported Adverse Events a

(22:52)

The Drug Development Process #drug discovery# clinical trials #post marketing surveillance

(14:24)

Post-Approval Economics for New Antibiotics: Post-Marketing Commitments and AST Development

(18:19)

EPISODE 25: Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act

(28:25)

Application of Pharmacoepidemiology Methods to CER and Global Research Network

(48:24)